NSE includes 6 securities under ST-ASM Stage I effective April 07, 2026, with enhanced margin requirements of 50% or existing margin (whichever is higher) applicable from April 08, 2026.
Impact
High
Severity
High
Justification
Directly affects trading conditions for 6 securities with significantly increased margin requirements, impacting traders holding or planning positions in these stocks from April 08, 2026.
List of securities subject to Reversal Trade Cancellation Mechanism (RTCM) for December 2025, covering over 300 stocks where specific trade cancellation procedures will apply.
Impact
Medium
Severity
Medium
Justification
Affects trading operations for over 300 securities with specific trade cancellation procedures. Important for traders and market participants dealing with these stocks to understand RTCM applicability.
Beta Drugs Limited's equity shares listed on NSE Capital Market Segment (Main Board) following migration from SME Emerge platform, effective November 13, 2025.
Impact
Medium
Severity
Medium
Justification
Significant corporate action involving migration from SME to Main Board, affecting trading and investor participation for Beta Drugs Limited
Beta Drugs Limited's equity shares are being listed on the NSE Main Board following migration from the SME Emerge platform, with shareholding pattern as of November 13, 2025.
Impact
Medium
Severity
Medium
Justification
Company migration from SME to Main Board is significant for existing shareholders and market participants, expanding trading opportunities and liquidity